Markets Stifel starts Kinnate Biopharma at buy; PT $32 Stifel launched coverage of Kinnate Biopharma (NASDAQ:KNTE) with a “buy” rating and $32 price target. The stock closed at $23.44 on Sept. 22. “Our positive thesis is based on the belief that the Phase 1 data for KIN... September 23, 2021